On Friday, Shares of DURECT Corporation (NASDAQ:DRRX), lost -0.38% to $2.60.
DURECT Corporation, declared that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT’s Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity, which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. It may also play an important role in protecting against acute kidney injury and other types of acute organ injury.
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), inclined 2.96% to $ 19.85, during its last trading session.
Momenta Pharmaceuticals, declared the closing of its underwritten public offering of 8,337,500 shares of its common stock at the public offering price of $19.00 per share, which comprises the exercise in full by the underwriters of their option to purchase 1,087,500 additional shares of common stock.
Goldman, Sachs & Co. and J.P. Morgan acted as joint book-running managers for the offering. Stifel acted as lead manager.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
At the end of Friday’s trade, Shares of W&T Offshore, Inc. (NYSE:WTI), gained 4.24% to $ 5.41.
W&T Offshore, declared a new discovery at Ewing Banks 910 and first production from the SS #6 well at Mississippi Canyon 538 field (“Medusa”), both in the deepwater of the Gulf of Mexico. The Company also offered an update on the status of the Big Bend and Dantzler deepwater development projects.
W&T made a new discovery at Ewing Banks 910 with the successful drilling and evaluation of the Ewing Banks 910 A-5 ST well. The Company logged 160 feet of gross hydrocarbon interval and is presently concluding the well. We expect recovery from the well to exceed our pre-drill estimates and we anticipate that the well could be online and flowing by the end of the second quarter. W&T has a 50% working interest in this well.
W&T Offshore, Inc., an independent oil and natural gas producer, together with its auxiliaries, engages in the acquisition, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas.
Finally, Bank of Nova Scotia (NYSE:BNS), ended its last trade with 1.37% gain, and close at $ 52.67.
Bank of Nova Scotia, stated second quarter net income of $1,797 million, in line with the same period last year. Diluted earnings per share were $1.42 contrast to $1.39 in the same period a year ago. Return on equity was 15.1% contrast to 16.3% last year.
“We delivered solid second quarter results, with earnings per share growth of 2% contrast to the same quarter last year,” said Brian Porter, President and CEO. “Our strong capital position, counting a Common Equity Tier 1 capital ratio of 10.6%, allows us to make further investments to better serve our customers and grow our well-diversified businesses.
Canadian Banking had a strong quarter, driven by a 12 basis point enhance in the net interest margin, in addition to good growth in retail and commercial loans and deposits. The expanded margin mostly results from our strategy to grow higher return businesses within our risk appetite. Wealth Administration continued to perform very well with 13% growth in assets under administration.
The Bank of Nova Scotia provides various personal, commercial, corporate, and investment banking services in Canada and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.